Crossmark

MZL: Hohe antitumorale Aktivität unter Mosunetuzumab

Crossref DOI link: https://doi.org/10.1007/s15004-025-1151-2

Published Online: 2025-10-15

Published Print: 2025-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wedekind, Silke
License Information

Text and Data Mining valid from 2025-10-01

Version of Record valid from 2025-10-01
More Information

Article History

First Online: 15 October 2025

Free to read: This content has been made available to all.